Prognostic value of quality of life scores in breast cancer patients undergoing preoperative chemotherapy.
Prognostic value of quality of life scores in breast cancer patients undergoing preoperative chemotherapy.
复制标题
接受术前化疗的乳腺癌患者生活质量评分的预后价值。
作者：
Takada K;Kashiwagi S;Fukui Y;Goto W;Asano Y;Morisaki M;Takashima T;Hirakawa K;Ohira M.
背景近年来，生活质量（QOL）评价已被公认为是多种癌症治疗的重要结局指标。在这项研究中，抗癌药物-乳腺（ACD-B）的生活质量评分是用来评估接受术前化疗（POC）的乳腺癌妇女的疾病特异性生存。结果300例乳腺癌患者经POC治疗后，生活质量明显下降（P <0.001），生活质量下降（P <0.001），生存质量下降（P<0.001）。POC前高QOL-ACD-B评分是总生存率多变量分析的独立因素（风险比0.26，95%置信区间）。结论术前QOL-ACD-B量表对乳腺癌患者行POC治疗有一定的临床意义。
BackgroundRecently, evaluation of quality of life (QOL) has been recognized as a significant outcome measure in the treatment of several cancers. In this study, the Anti-Cancer Drugs–Breast (ACD-B) QOL score was used to assess disease-specific survival in women with breast cancer undergoing preoperative chemotherapy (POC).MethodsQOL-ACD-B scores were evaluated before and after POC. The cut-off value of QOL-ACD-B contributing to events such as relapse or death was calculated by receiver operating characteristic (ROC) curve analysis.ResultsIn 300 women with breast cancer treated with POC, QOL was significantly reduced (P< 0·001). A high QOL-ACD-B score before POC was an independent factor in the multivariable analysis of overall survival (hazard ratio 0·26, 95 per cent c.i. 0·04 to 0·96).ConclusionEvaluation by QOL-ACD-B before POC may be useful to predict the prognosis of patients with breast cancer undergoing POC.